For US Healthcare Professionals US Prescribing Information Medication Guide CHOOSE INDICATIONDrugDrug name X NVAF: Reducing stroke risk DVT/PE: Treatment DVT Prophylaxis: After hip/knee replacement surgery Home Extensive Evidence Efficacy Profile ITT population Safety, as-treated population Real-world evidence: Stroke risk reduction Safety Profile Safety profile Real-world evidence: Major bleeding Real-world evidence: GI bleeding Real-world evidence: ICH bleeding Real-world evidence: Fatal bleeding Dosing Dose information Renal information Home Extensive Evidence Efficacy Profile Initial treatment Reduction in the risk of recurrence Real-world outcomes Safety Profile Principal safety outcome in initial treatment Major bleeding in initial treatment Safety outcome in recurrence risk reduction Real-world outcomes Dosing Dose information Starter Pack Home Extensive Evidence Efficacy Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Safety Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Dosing DOSING SWITCH AND MANAGEMENT Switching to/from XARELTO® Bleed management considerations Temporary discontinuation Other administration options ACCESS AND SUPPORT Formulary finder Janssen CarePath Program Janssen Prescription Assistance RESOURCES Reprints Patient resources Professional resources Other resources FAQs FAQs SEARCH XARELTO® DOSING: ALL INDICATIONS Search Important Safety Information US Prescribing Information Medication Guide For Non-US Visitors Patient Site Change Indication Choose Indication NVAF: Reducing stroke risk Extensive evidence Efficacy profile Safety profile Dosing DVT/PE: Treatment Extensive evidence Efficacy profile Safety profile Dosing DVT Prophylaxis: After hip/knee replacement surgery Extensive evidence Efficacy profile Safety profile Dosing Home Extensive Evidence Efficacy Profile ITT population Safety, as-treated population Real-world evidence: Stroke risk reduction Safety Profile Safety profile Real-world evidence: Major bleeding Real-world evidence: GI bleeding Real-world evidence: ICH bleeding Real-world evidence: Fatal bleeding Dosing Dose information Renal information Home Extensive Evidence Efficacy Profile Initial treatment Reduction in the risk of recurrence Real-world outcomes Safety Profile Principal safety outcome in initial treatment Major bleeding in initial treatment Safety outcome in recurrence risk reduction Real-world outcomes Dosing Dose information Starter Pack Home Extensive Evidence Efficacy Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Safety Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Dosing DOSING SWITCH AND MANAGEMENT Switching to/from XARELTO® Bleed management considerations Temporary discontinuation Other administration options ACCESS AND SUPPORT Formulary finder Janssen CarePath Program Janssen Prescription Assistance RESOURCES Reprints Patient resources Professional resources Other resources FAQs FAQs SEARCH XARELTO® DOSING: ALL INDICATIONS
NVAF: Reducing stroke risk Extensive evidence Efficacy profile Safety profile Dosing DVT/PE: Treatment Extensive evidence Efficacy profile Safety profile Dosing DVT Prophylaxis: After hip/knee replacement surgery Extensive evidence Efficacy profile Safety profile Dosing
XARELTO®: Stroke risk reduction in nonvalvular atrial fibrillation (NVAF) WHY WOULDN'T YOU CHOOSE A NOAC WITH EXTENSIVE EVIDENCE IN STROKE RISK REDUCTION? 24-HOUR STROKE RISK REDUCTION1,2 EFFICACY PROFILE PROVEN SAFETY PROFILE1 SAFETY PROFILE ONCE-DAILY dosing* *Taken with evening meal. DOSING TIME AND TIME AGAIN—extensive clinical trial and real-world evidence1,3-17 EXTENSIVE EVIDENCE NOAC = non-vitamin K antagonist oral anticoagulant. General Tags: NVAF: Reducing stroke risk
